Monday, November 14, 2016

Dynavax says U.S. FDA rejects its hepatitis B vaccine

Nov 14 (Reuters) - Dynavax Technologies Corp said

on Monday the U.S. Food and Drug Administration had rejected the

marketing application for its hepatitis B vaccine Heplisav-B,

sending the company's...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)